- High success rates for retinal therapies for macular degeneration
- Developing new treatments to reduce the risk of vision loss
- Offering clinical trials for treatments not available elsewhere
As we age, it's important to get regular eye exams to check for a condition called macular degeneration. It's the leading cause of loss of visual acuity or sharpness and the most common cause of legal blindness for people over age 65 in the United States.
Macular degeneration can negatively impact your life by affecting your ability to drive, read, do computer work and even recognize faces.
Yale Medicine eye specialists are at the forefront of developing better therapies for age-related macular degeneration, and they have improved their success in treating it to as high as 90 percent with some retinal therapies.
“At Yale Medicine, our center of attention is on the patient and the best outcome for patients and their families,” says Ron Adelman, MD, director of the Yale Medicine Retina & Macula Center, and professor of ophthalmology and visual science at Yale School of Medicine.